СИЕХ Чун-Мин (US),ХЬЮГУНИН Маргарет (US),МУРТАЗА Анвар (US),МакРАЙ Брэдфорд Л. (US),КУЦКОВА Юлия (US),МЕММОТТ Джон Э. (US),ПЕРЕС Дженнифер М. (US),ЧЖУН Сужу (US),ТАРКСА Эдит (US),КЛАББЕРС Анка (US),УО
申请号：
RU2015132478/10
公开号：
RU2015132478A
申请日:
2010.03.05
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. The antibody or antigen binding portion thereof comprising an antigen binding domain, wherein the antibody or antigen binding portion binds human IL-17, and the antigen binding domain contains six CRDs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3, where CDR-H1 has the SYGIS amino acid sequence (residues 31-35 of SEQ ID NO: 46) or a modification in the indicated amino acid sequence by substitution of at least one amino acid residue, where: the S substitution at position 1 is selected from the group consisting of G, T, V and R； the replacement of G in position 3 is selected from a group consisting of D, V, S, A, C, and I. Replacement of I at position 4 is selected from the group consisting of F, T, Y, M, and V； isamene S at position 5 is selected from the group consisting of G, C, N, V and H； CDR-H2 has the amino acid sequence GITPILGTANYAQKFQG (residues 50-66 of SEQ ID NO: 46) or a modification in the indicated amino acid sequence by substituting at least at least one amino acid residue, where: the I substitution at position 2 is V； the P substitution at position 4 is selected from the group consisting of H, N, T, L, I, V, S, and F； the I substitution at position 5 is selected from the group consisting of F, [[I,]] M, V, S and L； the replacement of L at position 6 is F； the replacement of G at position 7 is selected from groups consisting of M, L, E and A； the replacement of T at position 8 is selected from the group consisting of I, S, W, A, F, L, M, V and H； the replacement of A at position 9 is selected from the group, consisting of T, V, S, E, D, P, I, G and R； the N substitution at position 10 is selected from the group consisting of D, Y, S, T, V and I； isamene G at position 17 is D； CDR-H3 has the amino acid sequence E-P-N-D-F-W-N-G-Y-Y-T-T-H-H-F-D-Y (residues 99-115 of the sequence SEQ ID NO: 46) or a modification in the indicated amino acid sequence by substitution1. Антитело или его антигенсвязывающая часть, содержащие антигенсвязывающий домен,где
